Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018 2019

Details for Mechanism ID: 18018
Country/Region: Haiti
Year: 2017
Main Partner: FHI 360
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $2,616,452 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $400,000
Care: Pediatric Care and Support (PDCS) $41
Testing: HIV Testing and Counseling (HVCT) $245,996
Sexual Prevention: Other Sexual Prevention (HVOP) $1,126,796
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $224
Treatment: Adult Treatment (HTXS) $843,395
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 28,371
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative 2018 341
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative 2018 227
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 2,018
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 1,346
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative 2018 29
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative 2018 19
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative 2018 11,972
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative 2018 7,983
HTS_TST Sum of Test Result disaggregates 2018 2,371
HTS_TST_POS By Test Result: Positive 2018 2,371
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive 2018 129
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive 2018 86
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 205
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 135
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive 2018 32
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive 2018 21
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive 2018 1,229
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive 2018 820
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 38,668
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 14,520
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 550
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 53,738
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 16
PMTCT_STAT By Age (Numerator): Unknown Age 2018 14
PMTCT_STAT By Number of new negative: Unknown Age 2018 16
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 16
PMTCT_STAT_den By Age (Denominator): Unknown Age 2018 17
PP_PREV Age/sex: 15-19 Female 2018 1,580
PP_PREV Age/sex: 15-19 Male 2018 46
PP_PREV Age/sex: 20-24 Female 2018 1,586
PP_PREV Age/sex: 20-24 Male 2018 100
PP_PREV Age/sex: 25-49 Female 2018 5,883
PP_PREV Age/sex: 25-49 Male 2018 272
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 9,467
PP_PREV Sum of Age/Sex disaggregates 2018 9,467
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 33
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 33
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 33
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 33
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 8
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 6
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 14
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 15
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 9
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 6
TX_CURR Aggregated Age/Sex: 15+ Female 2018 1,390
TX_CURR Aggregated Age/Sex: 15+ Male 2018 927
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 2,317
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 2,317
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 2,317
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 1,227
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 927
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 2,154
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 2,154
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 2,317
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 1,741
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 48
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 3
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 34
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 1
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 939
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 106
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 549
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 61
TX_PVLS Numerator: Indication: Routine 2018 1,567
TX_PVLS Numerator: Indication: Targeted 2018 174
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 63
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 6
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 42
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 2
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 1,251
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 140
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 729
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 85
TX_PVLS_den Denominator: Indication: Routine 2018 2,085
TX_PVLS_den Denominator: Indication: Targeted 2018 232
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 7
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 4
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 11
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 15
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 9
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 5
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 554
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 12
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 6
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 6
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 17
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 12
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 331
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 194
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 56
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 56
TX_TB_den Denominator: By Screen Result: Negative 2018 542
TX_TB_den Denominator: By Screen Result: Positive 2018 12
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 110
Cross Cutting Budget Categories and Known Amounts Total: $2,716,452
Key Populations: Sex Workers $654,169
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: Gender Based Violence (GBV) $100,000
Post GBV Care
Key Populations: MSM and TG $1,962,283
GBV Prevention
Post GBV Care